A medical device can be designated for the De Novo pathway when it offers novel technology with a reasonable assurance of ...
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results